Next generation antiviral screening
NeoVirTech has developed a breakthrough technology to directly visualize and quantify in real time virus infection and replication in living cells. NeoVirTech possesses the exclusive worldwide license for the ANCHORTM technology, a new generation of autofluorescent system allowing the visualization of DNA in living cells.
The ANCHOR system is composed of two parts:
- The ANCH sequence: short (from 200NT to 1kb) and unique (non repetitive), it contains sequence that contains nucleation seeds for the binding of OR proteins. Insertion of the sequence does not perturb chromatin assembly or create fragile sites in the target DNA.
- The OR-fluorescent protein expressing gene which specifically recognizes and spreads on the ANCH sequence, triggering the formation of a fluorescent focus easily detectable and quantifiable by microscopy (either classical or High content).
The ANCH sequence is cloned upstream of the Or-FP expressing gene, therefore, this ANCHOR cassette will convert the target DNA into an autofluorescent molecule (plasmid, gene, transposon, virus). For small viruses, ANCH and OR sequences are used separately.
NeoVirTech uses four different ANCHOR systems with different length and fused to their corresponding fluorescent proteins that can be used in combinations to detect several class of DNA simultaneously. Using the ANCHORTM technology, fitness studies visualizing co-infection of several viruses in real time are now possible.
High content Screening
Our models are conceived specifically for high content screening campaign. We offer several screening models for antiviral discovery in human and animal health and propose screening services using customer models (viral or not) and our internal compound libraries.
- Library collection and formatting
- Screening of antiviral activities on one or several viral models and on one or several cell lines (Viral inactivation, attachment, penetration, replication, cell to cell spread).
- IC50/90 calculation
- Toxicity testing
- Hit sorting
- Hit optimization
NeoVirTech develops custom autofluorescent viruses or viral vectors for a specific application such as antiviral discovery, gene transfer studies, viral based vaccine development, oncolytic vectors and other broad applications, depending on customer’s interest.
- Viral vector collection and amplification
- ANCHORTM tagged version of the virus of interest and validation
- Production of the autofluorescent vector
- Determination of antiviral activities on this specific construct
NeoVirTech offers the ANCHORTM technology for internal use by licensing.
- Access to the ANCHORTM technology and generation of specific construct if needed
- Transfer of the ANCHORTM technology to the customer's R&D laboratory
- Technical support and troubleshooting
What our clients say
For almost 40 years, InvivoGen had developed and commercialized several hundreds of compounds for innate immunity field. We are interested in testing the activity of some new proprietary compounds in the anti-infectious domain. NeoVirTech was a ‘local’ choice for this project. The technology they proposed combined quantitative and qualitative results in a high throughput screening format. Their expertise in virology, the speed and quality of the generated data led us to rapidly identify new compounds as antiviral.
Dr Cédric BoularanInvivoGen, SAS, Toulouse
Neovirtech’s technology platform uniquely allows rapid and accurate screening of compounds against a range of clinically relevant viral pathogens. Dr. Franck Gallardo and his team provide an in-depth knowledge base and an interactive environment for study design, planning and execution. I would highly recommend Neovirtech for antiviral drug screening
Dr Erik De LeeuwInstitute of Human Virology & Department of Biochemistry and Molecular Biology of the University of Maryland Baltimore School of Medicine, USA
Advances in immune suppression allows the grafting of life saving cells and organs between patients. Immune suppression unfortunately also promotes viral infections normally controlled by the immune system making the development of novel antivirals that work under immune suppression an imperative task. The underlying mechanisms causing reactivation or promoting viral replication are often related to dynamic changes in the chromatin status of the viral genome. Working with NeoVirtech gives us the unique opportunity to label viral genomes with the ANCHOR technology and study the dynamic behaviour of individual viral genomes in living cells under different environmental conditions. Understanding how viral genomes respond in living cells is key to understanding and developing novel drug concepts and mechanistic understanding of existing antivirals. Setting up the technology with NeoVirtech was simple, professional and driven by scientific understanding … the start of a great ongoing relationship!
Dr Harald WodrichMFP CNRS UMR 5234, University of Bordeaux
Viral diseases cause significant financial loss in animal production systems. Despite the importance of viral pathogens as primary and secondary etiologic agents in cattle, pigs and poultry, no antiviral products are commercially licensed for use in veterinary medicine. Collaboration with NeoVirTech give us unique opportunity to explore the potential of antiviral therapy in the veterinary virology domain. Among viral animal diseases, we are particularly interested in poxviruses induced diseases of rabbit and poultry (myxomatosis, fowlpox), and labelling of DNA viral genomes with the ANCHOR technology will allow us to rapidly screen available compounds for antiviral significative effects.
Dr Stéphane BertagnoliProfessor of virology, National Veterinary school of Toulouse
Expertise and outstanding skills that rely on R&D of high scientific level.
This company, a true example of dynamism and inventiveness, is a pride for our institute.
Dr. Bernard DucommunHead of ITAV lab
Based on 25 years of research in the macrocyclic chemistry field, we had accumulated several hundreds of compounds in the lab that were developed for human health. We were interested in testing the activity of these compounds in the anti-infectious domain. NeoVirTech was immediately responsive for this project, and with high professionalism, completely met our needs. Their expertise in screening and the speed and quality of the generated data led us to rapidly identify 3 hit compounds in our library as new inhibitors of hCMV. These results have been recently published and highlighted by the cover of ACS infectious disease in august 2015. Without the expert assistance of NeoVirTech, it would have been impossible to rapidly test and value our library, opening new perspectives for our research activities. Thank you NeoVirTech for this beautiful and precious collaboration.
Prof. Claude P. GrosICMUB, Bourgogne Franche-Comté University
Dr A.F Tilkin-MariaméInserm
NeoVirTech SAS, a biotechnology company developing autofluorescent viruses to decipher viral infection in vivo and to detect and measure antiviral activities started a collaboration with Transgene SA, a biopharmaceutical company […]
NeoVirTech is awarded at the National contest for innovative companies (ILab) organized by BPI France and the French Ministry. The ANTIPOX project founded by this prestigious price will aim at […]
NeoVirTech’s CEO, Franck Gallardo, presented the internal high content microscopy service for antiviral screening and discovery during the Drug discovery by phenotypic screening session. Thanks to ELRIGfr organizer […]
Some facts about us
The company combines custom R&D platform and screening services for the development of autofluorescent viruses or viral vectors and their use in screening campaign for the discovery of antiviral molecules for human and animal health. NeoVirTech customers include academic laboratories, biotechnology companies and large pharmaceutical industries. The company capitalizes on its exclusive worldwide license of the ANCHOR technology, a new generation of fluorescent DNA tagging system, which allows direct imaging of viral infection and replication in living cells. Localized at the heart of the Oncopole in Toulouse, France, NeoVirTech won the Innovative Company Award from the French Ministry of Higher Education and Research as well as The French Agency for Innovation (BPI France) in 2013 and was nominated in 2015 and selected at the worldwide innovation contest in 2016.Franck Gallardo, PhD President & CEO
Franck Gallardo, PhDFounder & Scientific manager
Franck has over 10 years of experience in the field of cellular biology and microscopy. He holds a PhD in biochemistry from the medicine faculty of the Université de Montréal, Qc, CANADA (2010). In 2012, Franck takes the lead of the ANCHOR team at the Technological Institute for Life Sciences and is responsible for the industrial application of the ANCHOR system. In 2015, he is awarded alumnus of the year from the Riboclub society.
Bruno Brisson, MScAssociate, Business developper, BLS consulting
Bruno held various positions in Business, Sales and Marketing and management (President and CEO of Biospace Lab). Bruno created his company, BLS consulting, in 2011 and accompanied more than fifteen biotech/medtech companies for business and corporate development in preclinical research and dermocosmetics (actives, biomarkers, imaging, in-silico modeling, molecules, predictive toxicology) Bruno is a long-time collaborator of NeoVirTech and bring his business development expertise to the team.
Kerstin Bystricky, PhD/PrAssociate, scientific council
Kerstin has over 20 years of experience in the field of cellular biology and DNA dynamics. She holds an engineer diploma from AgroParisTech (Paris) and PhD in biochemistry from the PenState university (USA). She is principal investigator of the chromatin and gene expression team at the Eucaryotic molecular biology laboratory (Toulouse). Kerstin co-developped the ANCHOR system with Franck back in 2010. She brings her expertise in DNA dynamics and cell biology to the team and is responsible for developping new application for the ANCHOR system. Visit her research ID page
Bernard Mariamé, PhDAssociate, scientific council
Bernard has over 30 years of experience in immunology and virology. Following his thesis in immunogenetics (1979), he did a post-doc in Francois Rougeon lab at the Institut Pasteur (Paris) followed by a second post doc at the Ludwig Institute in Bruxelles (Belgium). Bernard was recruited as a researcher first class at the CNRS in 1990. Bernard is expert in the virology field, especially herpes viruses biology, he is member and financial officer of the HerPas association. Bernard joined the team in 2012, bringing his virology expertise and his technical skills to the team.
Hicham Saad, PhDBusiness developer North America
Hicham is a junior business developer located in Calgary, Alberta (CA). He is in charge of prospecting and developing NeoVirTech customer network in North America. Hicham holds a PhD in Cell biology from the University of Toulouse. His major is on the ANCHORTM technology.